Discover 1,141 paid clinical trials in Waterbury, Connecticut. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,141
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
for
Hepatocellular Carcinoma
Location: New Haven CT, New York NY, New Brunswick NJ, Newark DE,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06921785
Phase3, Recruiting
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
for
Advanced Solid Tumors That Are MTAP Deficient
Location: New Haven CT, Providence RI, Baltimore MD, Fairfax VA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06130553
Phase1, Phase2, Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
for
Delayed Graft Function, DGF, Kidney Transplant
Location: New Haven CT, New York NY, Livingston NJ,
Sponsor: Alexion Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT06830798
Phase3, Recruiting
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
for
Acute Coronary Syndrome
Location: New Haven CT, Hartford CT, Stony Brook NY,
Sponsor: DalCor Pharmaceuticals
Sex: All
Age: 45+
Code: NCT05918861
Phase3, Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
for
Non-small Cell Lung Cancer
Location: New Haven CT, New York NY, Brooklyn NY, Montreal,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06350097
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
for
Polymyositis, Dermatomyositis
Location: New Haven CT, Great Neck NY, Boston MA, Baltimore MD,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT06455449
Phase3, Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
for
Breast Cancer
Location: New Haven CT, Stony Brook NY, New York NY,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06103864
Phase3, Recruiting
Prevalence of Carbohydrate Intolerance in Lean and Obese Children